Zelira Therapeutics Ltd logo

Zelira Therapeutics Ltd

ASX:ZLD (Australia)  
A$ 0.37 (0%) Jun 21
At Loss
Market Cap:
A$ 4.20M ($ 2.79M)
Enterprise V:
A$ 5.86M ($ 3.89M)
Volume:
18.11K
Avg Vol (2M):
8.37K
Trade In:
Volume:
18.11K
At Loss
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Zelira Therapeutics Ltd ( ASX:ZLD ) from 2003 to Jun 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Zelira Therapeutics stock (ASX:ZLD) PE ratio as of Jun 24 2024 is 0. More Details

Zelira Therapeutics Ltd (ASX:ZLD) PE Ratio (TTM) Chart

To

Zelira Therapeutics Ltd (ASX:ZLD) PE Ratio (TTM) Historical Data

Total 1293
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Zelira Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-24 At Loss 2024-04-22 At Loss
2024-06-21 At Loss 2024-04-19 At Loss
2024-06-20 At Loss 2024-04-18 At Loss
2024-06-19 At Loss 2024-04-17 At Loss
2024-06-18 At Loss 2024-04-16 At Loss
2024-06-17 At Loss 2024-04-15 At Loss
2024-06-14 At Loss 2024-04-12 At Loss
2024-06-13 At Loss 2024-04-11 At Loss
2024-06-12 At Loss 2024-04-10 At Loss
2024-06-11 At Loss 2024-04-09 At Loss
2024-06-10 At Loss 2024-04-08 At Loss
2024-06-07 At Loss 2024-04-05 At Loss
2024-06-06 At Loss 2024-04-04 At Loss
2024-06-05 At Loss 2024-04-03 At Loss
2024-06-04 At Loss 2024-04-02 At Loss
2024-06-03 At Loss 2024-04-01 At Loss
2024-05-31 At Loss 2024-03-29 At Loss
2024-05-30 At Loss 2024-03-28 At Loss
2024-05-29 At Loss 2024-03-27 At Loss
2024-05-28 At Loss 2024-03-26 At Loss
2024-05-27 At Loss 2024-03-25 At Loss
2024-05-24 At Loss 2024-03-22 At Loss
2024-05-23 At Loss 2024-03-21 At Loss
2024-05-22 At Loss 2024-03-20 At Loss
2024-05-21 At Loss 2024-03-19 At Loss
2024-05-20 At Loss 2024-03-18 At Loss
2024-05-17 At Loss 2024-03-15 At Loss
2024-05-16 At Loss 2024-03-14 At Loss
2024-05-15 At Loss 2024-03-13 At Loss
2024-05-14 At Loss 2024-03-12 At Loss
2024-05-13 At Loss 2024-03-11 At Loss
2024-05-10 At Loss 2024-03-08 At Loss
2024-05-09 At Loss 2024-03-07 At Loss
2024-05-08 At Loss 2024-03-06 At Loss
2024-05-07 At Loss 2024-03-05 At Loss
2024-05-06 At Loss 2024-03-04 At Loss
2024-05-03 At Loss 2024-03-01 At Loss
2024-05-02 At Loss 2024-02-29 At Loss
2024-05-01 At Loss 2024-02-28 At Loss
2024-04-30 At Loss 2024-02-27 At Loss
2024-04-29 At Loss 2024-02-26 At Loss
2024-04-26 At Loss 2024-02-23 At Loss
2024-04-25 At Loss 2024-02-22 At Loss
2024-04-24 At Loss 2024-02-21 At Loss
2024-04-23 At Loss 2024-02-20 At Loss

Zelira Therapeutics Ltd (ASX:ZLD) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.